Switzerland's Serono is voluntarily recalling a number of batches ofCrinone (progesterone vaginal gel) 4% and 8% (for use in the treatment of infertility in women) due to a drug application problem in some applicators.
This recall is a response to complaints which subsequently were investigated by Columbia Laboratories, the manufacturer of Crinone. An investigation by Columbia Labs has determined that the gel may change in its consistency over time in these recalled batches. This may result in the gel being partially expelled when opening the applicator prior to administration, according to a Serono statement.
Serono acquired the exclusive rights throughout most of the world to Crinone, which achieved sales of $27.4 million in 2000, from Wyeth-Ayerst in 1999.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze